NeuroVive Pharmaceutical AB (NVP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NeuroVive Pharmaceutical AB (NVP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH82675D
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

NeuroVive Pharmaceutical AB (NeuroVive), formerly NeuroPharma i Sverige AB focuses on the research and development of mitochondrial therapies. The company's programs include NeuroSTAT, a clinical phase II drug candidate for the prevention of traumatic brain injury; and phase I KL1333, a novel small molecule drug that is being developed for the treatment of genetic mitochondrial disorders. NeuroVive carries out research programs in the areas of mitochondrial disorders, including complex I dysfunction; non-alcoholic steatohepatitis (NASH); and hepatocellular cancer among others. The company works in collaboration with research institutions, academic and other pharmaceutical companies for drug development. NeuroVive is headquartered in Lund, Sweden.

NeuroVive Pharmaceutical AB (NVP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

NeuroVive Pharma Acquires Cyclophilin Inhibitors From Biotica 12

Partnerships 13

NeuroVive Pharma Enters into Collaboration Agreement with University of Florida 13

NeuroVive Pharma Enters into Agreement with Children's Hospital of Philadelphia 14

NeuroVive Pharma Enters into Agreement with Karolinska Institutet 15

NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 16

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 17

NeuroVive Pharma Extends Agreement with Hospices Civils de Lyon 18

NeuroVive Pharma Extends Agreement with Hospices Civils de Lyon for Pre-clinical R&D Programs 19

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 20

NeuroVive Enters Into Co-Development Agreement With Isomerase Therapeutics For Cyclophilin-Inhibiting Molecules 21

Licensing Agreements 22

Fortify Therapeutics Enters into Licensing Agreement with NeuroVive Pharma 22

NeuroVive Pharma Enters into Licensing Agreement with Yungjin Pharm 23

NeuroVive Pharma Enters Into Licensing Agreement With Sihuan Pharma For CicloMulsion And NeuroStat 24

Equity Offering 26

NeuroVive Pharma Raises USD9.8 Million in Rights Offering of Units 26

NeuroVive Pharma Raises USD0.6 Million in Private Placement of Shares 28

NeuroVive Pharma Raises USD0.5 Million in Second Tranche of Private Placement of Units 29

NeuroVive Pharma Raises USD0.5 Million in First Tranche of Private Placement of Units 30

NeuroVive Pharma Raises USD11 Million in Right Offering of Units 31

NeuroVive Pharma Raises USD8.5 Million in Private Placement of Shares 33

NeuroVive Pharma Raises USD7.8 Million in Private Placement of Shares 34

NeuroVive Pharmaceutical Raises USD3.3 Million in Initial Public Offering 35

NeuroVive Pharmaceutical Asia Raises USD3.25 Million in Private Placement 36

NeuroVive Pharma Completes Rights Offering Of Shares For USD 11.5 Million 37

NeuroVive Pharma Completes Private Placement Of Shares For USD 5.3 Million 39

Neurovive Pharma Plans Public Offering Of Shares 41

Neurovive Pharma Completes Rights Offering of Shares for USD8 Million 42

Acquisition 43

NeuroVive Pharma Acquires Additional 5% Stake in Isomerase Therapeutics for USD0.8 Million 43

NeuroVive Pharma Acquires 5% Stake in Isomerase Therapeutics for USD0.8 Million 44

NeuroVive Pharmaceutical AB-Key Competitors 45

NeuroVive Pharmaceutical AB-Key Employees 46

NeuroVive Pharmaceutical AB-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Financial Announcements 48

Aug 21, 2018: NeuroVive Pharmaceutical reports interim report January-June 2018 48

May 22, 2018: NeuroVive Pharmaceutical Interim report January-March 2018 49

Feb 20, 2018: NeuroVive Pharmaceutical Year End Report January-December 2017 50

Nov 21, 2017: NeuroVive Pharmaceutical Interim Report January-September 2017 51

Aug 17, 2017: NeuroVive Pharmaceutical Interim report January-June 2017 52

May 18, 2017: NeuroVive Pharmaceutical Interim Report January-March 2017 55

Feb 21, 2017: NeuroVive Pharmaceutical Year End Report January-December 2016 56

Corporate Communications 58

Nov 07, 2017: NeuroVive Board Chair Resigns, New Chair Elected 58

Feb 22, 2017: NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma 59

Clinical Trials 60

Apr 20, 2017: NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects 60

Apr 05, 2017: NeuroVives lead NASH project to be presented at The International Liver Congress 61

Feb 02, 2017: NeuroVive's new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells 62

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63

List of Figures

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NeuroVive Pharmaceutical AB, Deals By Therapy Area, 2012 to YTD 2018 9

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroVive Pharma Acquires Cyclophilin Inhibitors From Biotica 12

NeuroVive Pharma Enters into Collaboration Agreement with University of Florida 13

NeuroVive Pharma Enters into Agreement with Children's Hospital of Philadelphia 14

NeuroVive Pharma Enters into Agreement with Karolinska Institutet 15

NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 16

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 17

NeuroVive Pharma Extends Agreement with Hospices Civils de Lyon 18

NeuroVive Pharma Extends Agreement with Hospices Civils de Lyon for Pre-clinical R&D Programs 19

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 20

NeuroVive Enters Into Co-Development Agreement With Isomerase Therapeutics For Cyclophilin-Inhibiting Molecules 21

Fortify Therapeutics Enters into Licensing Agreement with NeuroVive Pharma 22

NeuroVive Pharma Enters into Licensing Agreement with Yungjin Pharm 23

NeuroVive Pharma Enters Into Licensing Agreement With Sihuan Pharma For CicloMulsion And NeuroStat 24

NeuroVive Pharma Raises USD9.8 Million in Rights Offering of Units 26

NeuroVive Pharma Raises USD0.6 Million in Private Placement of Shares 28

NeuroVive Pharma Raises USD0.5 Million in Second Tranche of Private Placement of Units 29

NeuroVive Pharma Raises USD0.5 Million in First Tranche of Private Placement of Units 30

NeuroVive Pharma Raises USD11 Million in Right Offering of Units 31

NeuroVive Pharma Raises USD8.5 Million in Private Placement of Shares 33

NeuroVive Pharma Raises USD7.8 Million in Private Placement of Shares 34

NeuroVive Pharmaceutical Raises USD3.3 Million in Initial Public Offering 35

NeuroVive Pharmaceutical Asia Raises USD3.25 Million in Private Placement 36

NeuroVive Pharma Completes Rights Offering Of Shares For USD 11.5 Million 37

NeuroVive Pharma Completes Private Placement Of Shares For USD 5.3 Million 39

Neurovive Pharma Plans Public Offering Of Shares 41

Neurovive Pharma Completes Rights Offering of Shares for USD8 Million 42

NeuroVive Pharma Acquires Additional 5% Stake in Isomerase Therapeutics for USD0.8 Million 43

NeuroVive Pharma Acquires 5% Stake in Isomerase Therapeutics for USD0.8 Million 44

NeuroVive Pharmaceutical AB, Key Competitors 45

NeuroVive Pharmaceutical AB, Key Employees 46

NeuroVive Pharmaceutical AB, Subsidiaries 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

NeuroVive Pharmaceutical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com